

## **Press release**

Stockholm November 13, 2006

### **Issue of new shares in Biovitrum AB (publ)**

In accordance with Biovitrum's 2001/2006 warrant programme, 8,000 shares have been issued at SEK 59 per share, with net proceeds of SEK 472,000. The remaining 147,500 warrants under the 2001/2006 programme, each entitle to subscribe for two shares, expires on November 30, 2006.

Following above mentioned issue, the total number of shares outstanding amounts to 45,327,700.

#### **For additional information, please contact:**

Mats Pettersson, CEO of Biovitrum AB

+46 8 697 23 27, e-mail address: [mats.pettersson@biovitrum.com](mailto:mats.pettersson@biovitrum.com)

Anna Karin Källén, Vice President, Communications and IR

+46 8 697 20 85, e-mail address: [annakarin.kallen@biovitrum.com](mailto:annakarin.kallen@biovitrum.com)

#### **BIOVITRUM IN SHORT**

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum focuses on drugs for the treatment of obesity, diabetes, inflammation and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately USD 119 million and approximately 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see [www.biovitrum.com/](http://www.biovitrum.com/).